ReviewChinese medical journal2015
Current and Future Clinical Applications of Zinc Transporter-8 in Type 1 Diabetes Mellitus.
Review in Chinese medical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- SLC30A8 (ZnT8) at the crossroads of epigenetics and microRNA regulation in type 2 diabetes and nephropathy.World journal of nephrology · 2026Review
- Proteomic Changes in Patients with LADA-Type Diabetes: Prospects for Diagnostic Biomarkers.International journal of molecular sciences · 2026Review
- Changes of B cell subsets in different types of diabetes and its effect on the progression of latent autoimmune diabetes in adults.Endocrine · 2024Article
- Potential clinical implications of molecular mimicry-induced autoimmunity.Immunity, inflammation and disease · 2024Review
- Vaccine for Diabetes-Where Do We Stand?International journal of molecular sciences · 2022Review
- rs3806265 and rs4612666 of theFrontiers in endocrinology · 2022Article
- Zinc transporter 8 autoantibody in the diagnosis of type 1 diabetes in children.Clinical and experimental pediatrics · 2020Article
- Polymorphisms of theDiabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- Genetic, Functional, and Immunological Study of ZnT8 in Diabetes.International journal of endocrinology · 2019Review
- Polymorphisms inJournal of diabetes research · 2019Article
- Gut microbiome in type 1 diabetes: A comprehensive review.Diabetes/metabolism research and reviews · 2018Review
- Prevalence of ZnT8 Antibody in Turkish Children and Adolescents with New Onset Type 1 DiabetesJournal of clinical research in pediatric endocrinology · 2018Article
- Prokaryotic expression and characterization of the heterodimeric construction of ZnT8 and its application for autoantibodies detection in diabetes mellitus.Microbial cell factories · 2017Article
- A UNIQUE CASE OF ATEZOLIZUMAB-INDUCED AUTOIMMUNE DIABETES.AACE clinical case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the utility of zinc transporter-8 (ZnT8) in the improvement of type 1 diabetes mellitus (T1DM) diagnosis and prediction, and to explore whether ZnT8 is a potential therapeutic target in T1DM. DATA SOURCES: A search was conducted within the medical database PubMed for relevant articles published from 2001 to 2015. The search terms are as follows: "ZnT8," "type 1 diabetes," "latent autoimmune diabetes in adults," "type 2 diabetes," "islet autoantibodies," "zinc supplement," "T cells," "β cell," "immune therapy." We also searched the reference lists of selected articles. STUDY SELECTION: English-language original articles and critical reviews concerning ZnT8 and the clinical applications of islet autoantibodies in diabetes were reviewed.
resultsThe basic function of ZnT8 is maintaining intracellular zinc homeostasis, which modulates the process of insulin biosynthesis, storage, and secretion. Autoantibodies against ZnT8 (ZnT8A) and ZnT8-specific T cells are the reliable biomarkers for the identification, stratification, and characterization of T1DM. Additionally, the results from the animal models and clinical trials have shown that ZnT8 is a diabetogenic antigen, suggesting the possibility of ZnT8-specific immunotherapy as an alternative for T1DM therapy.
conclusionsZnT8 is a novel islet autoantigen with a widely potential for clinical applications in T1DM. However, before the large-scale clinical applications, there are still many problems to be solved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.